Patent application number | Description | Published |
20080280954 | Method of Improving Wakefulness - The present invention relates to the use of certain imidazolylalkyl-pyridines as wakefulness compounds. | 11-13-2008 |
20090105333 | MELATONIN AGONIST TREATMENT - This invention provides methods of administering (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclo-propyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder. | 04-23-2009 |
20090209638 | TREATMENT FOR DEPRESSIVE DISORDERS - A method of treating depression comprising administering a melatonin agonist. | 08-20-2009 |
20090298880 | METHODS FOR THE ADMINISTRATION OF ILOPERIDONE - The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms. | 12-03-2009 |
20090306137 | TREATMENT FOR DEPRESSIVE DISORDERS - A method of treating depression comprising administering a melatonin agonist. | 12-10-2009 |
20100261786 | PREDICTION OF SLEEP PARAMETER AND RESPONSE TO SLEEP-INDUCING COMPOUND BASED ON PER3 VNTR GENOTYPE - The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem repeat (VNTR) genotype. | 10-14-2010 |
20100273809 | METHOD AND COMPOSITION FOR TREATING AN ALPHA ADRENOCEPTOR-MEDIATED CONDITION - Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions. | 10-28-2010 |
20110021566 | GENETIC MARKERS FOR EFFICACY OF ILOPERIDONE IN THE TREATMENT OF PSYCHOTIC SYMPTOMS - Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction. | 01-27-2011 |
20110044971 | METHOD AND COMPOSITION FOR TREATING A SERATONIN RECEPTOR-MEDIATED CONDITION - A method and composition for treating serotonin receptor-mediated conditions. | 02-24-2011 |
20110118313 | IDENTIFICATION OF A MOLECULAR SIGNATURE FOR ANTIPSYCHOTICS AND SERMS - Molecular signature for antipsychotics and SERMs has been identified, namely their upregulation of genes that alter lipid homeostasis, preferably of one or more of the following genes: TNSIG1, SCD, FADS2, LDLR, FDPS, ACAT2, FDFT1, CYP51A1, FASN, DHCR7, RAB26, TM7SF2, SATB1, FAM117, GPNMB, NUPR1, VAC14, and LSS. | 05-19-2011 |
20120027871 | METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE - The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation. | 02-02-2012 |
20120136050 | USE OF A MELATONIN AGONIST FOR THE TREATMENT OF SLEEP DISORDERS INCLUDING PRIMARY INSOMNIA - Embodiments of the invention include the treatment of a sleep disorder comprising the administration of N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cycloproply]methyl]propanamide or a salt, stereoisomer, solvate, or hydrate thereof, in amorphous or crystalline form. | 05-31-2012 |
20130197076 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 08-01-2013 |
20140079685 | METHOD AND COMPOSITION FOR TREATING A SEROTONIN RECEPTOR-MEDIATED CONDITION - A method and composition for treating serotonin receptor-mediated conditions. | 03-20-2014 |
20140194459 | METHOD AND COMPOSITION FOR TREATING AN ALPHA ADRENOCEPTOR-MEDIATED CONDITION - Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions. | 07-10-2014 |
20140296330 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 10-02-2014 |
20140296331 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 10-02-2014 |
20140296332 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 10-02-2014 |
20140357710 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 12-04-2014 |
20150025086 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 01-22-2015 |
20150045390 | ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS - R-P88 is used for the treatment of disorders amenable to treatment with an atypical antipsychotic. | 02-12-2015 |
20150080464 | MELATONIN AGONIST TREATMENT - Melatonin Agonist, MA-1, is administered at effective doses. | 03-19-2015 |